Methicillin-resistant Staphylococcus aureus bacterial membrane (MRSA membrane)

The Methicillin-resistant Staphylococcus aureus (MRSA) bacterial membrane is a complex phospholipid bilayer that serves as the primary interface between the cytoplasm and the external environment. It is essential for maintaining cellular homeostasis, regulating osmotic pressure, and facilitating the transport of ions and nutrients through specialized transport proteins (Miller et al., 2016, Journal of Lipid Research). Beyond its structural role, the membrane acts as a platform for critical enzymatic processes, including the synthesis of the peptidoglycan cell wall and the generation of adenosine triphosphate (ATP) via the electron transport chain (Ernst and Peschel, 2011, Nature Reviews Microbiology). In MRSA, the membrane is a key therapeutic target for lipopeptide antibiotics like daptomycin, which inserts into the bilayer in a calcium-dependent manner to cause rapid depolarization and cell death (Humphries et al., 2013, Clinical Infectious Diseases). Additionally, newer lipoglycopeptides such as telavancin and oritavancin utilize membrane disruption as a secondary mechanism of action to overcome resistance (Saravolatz et al., 2009, Clinical Infectious Diseases). Understanding the composition and charge of the MRSA membrane is vital, as the bacteria can develop resistance by modifying membrane lipids to reduce the binding affinity of cationic antimicrobial agents (Bayer et al., 2013, Annals of the New York Academy of Sciences).

Other names

Methicillin-resistant Staphylococcus aureus cytoplasmic membraneMRSA cell membraneMRSA plasma membraneStaphylococcus aureus bacterial membrane

Drugs targeting the MRSA membrane typically act through calcium-dependent insertion into the lipid bilayer, leading to rapid depolarization, loss of membrane potential, and leakage of intracellular ions (e.g., potassium), which results in the cessation of DNA, RNA, and protein synthesis and subsequent cell death (Humphries et al., 2013, Clinical Infectious Diseases). Some agents also bind to Lipid II to simultaneously inhibit cell wall synthesis (Saravolatz et al., 2009, Clinical Infectious Diseases).